Close

Sangamo Biosciences (SGMO) Granted FDA Orphan Drug Designation for SB-318 Genome Editing Treatment

January 11, 2017 7:30 AM EST Send to a Friend
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login